SCHEMBL4746310

SCHEMBL4746310

Cc1ccc2c(c1)c(-c1cccc(-c3cc4c5ccc(C)c6c5c(cc4c4ccc(C)cc34)-c3ncccc3-6)c1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.34
MAP4K4 O95819 2/20 0.33
BRD4 O60885 1/20 0.32
MAP2K4 P45985 2/20 0.32
TGFBR1 P36897 1/20 0.31
LMNA P02545 2/20 0.31
CHEK1 O14757 1/20 0.31
ABL1 P00519 1/20 0.31
NTRK1 P04629 1/20 0.31
LCK P06239 1/20 0.31
FYN P06241 1/20 0.31
CSF1R P07333 1/20 0.31
MET P08581 1/20 0.31
PDGFRB P09619 1/20 0.31
PIM1 P11309 1/20 0.31
FGFR1 P11362 1/20 0.31
PDGFRA P16234 1/20 0.31
PRKACA P17612 1/20 0.31
LTK P29376 1/20 0.31
GRK5 P34947 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746312 0.96 BCHE (0.34) BCHEMAP4K4TGFBR1LMNAKDM4E
SCHEMBL4746339 0.93 DHODH (0.36) BCHEMAP2K4TGFBR1LMNAKDM4E
SCHEMBL4745843 0.92 BCHE (0.40) BCHEMAP2K4LMNAKDM4EMEN1
SCHEMBL4746317 0.92 DHODH (0.35) BCHELMNAKDM4EMEN1ALDH1A1
SCHEMBL4745792 0.91 BCHE (0.40) BCHELMNAKDM4EMEN1ALDH1A1
SCHEMBL4746389 0.91 DHODH (0.34) BCHETGFBR1LMNAABL1KDM4E
SCHEMBL4746394 0.91 MEN1 (0.32) BCHEGSK3BKDM4EMEN1ALDH1A1
SCHEMBL4746387 0.90 DHODH (0.33) BCHETGFBR1LMNAKDM4EALDH1A1
SCHEMBL4745791 0.90 BCHE (0.37) BCHEMAP2K4LMNAADORA1KDM4E
SCHEMBL4745812 0.88 ALDH1A1 (0.34) BCHEABL1KDRADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 BCHE 376/4885MAP4K4 4127/4885BRD4 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.